Franklin Biolabs

Executive Summary

Franklin Biolabs is a fully integrated preclinical contract research organization (CRO) headquartered in Philadelphia, specializing in cell and gene therapy development. Founded in 2019, the company offers end-to-end services encompassing vector production, CMC analytics, and preclinical toxicology studies, supporting biotech, pharma, and academic clients from discovery through IND submission. Leveraging a state-of-the-art facility and deep expertise, Franklin Biolabs addresses the growing demand for specialized CRO services in the cell and gene therapy space, a market projected to expand significantly as more therapies advance toward clinical trials. The company's integrated model positions it to capture value as clients seek streamlined development timelines and regulatory support. While Franklin Biolabs operates in a competitive CRO landscape, its focus on cutting-edge modalities and early-stage engagement provides differentiation. The company's private status and pre-clinical stage suggest it may be poised for growth through strategic partnerships or capacity expansions, though specific financial details and client contracts are not disclosed.

Upcoming Catalysts (preview)

• Q3 2026Facility Expansion or New Lab Capacity70% success
• Q4 2026Major Partnership or Client Win with Large Pharma50% success
• Q1 2027Completion of Key IND-Enabling Studies for a Client60% success